Introduction
COVID-19 is a worldwide pandemic disease that caused respiratory symptoms and severe systemic complications. In August 2021, the FDA approved the first mRNA COVID-19 vaccine known as the Pfizer-BioNTech COVID-19 Vaccine (ComirnatyTM) to prevent COVID-19 in adult patients. Common reported cutaneous adverse reactions were delayed large local reactions, swelling, urticarial rash, and flare existing dermatologic conditions.2,3,4,5 However, only a few cases of the subepidermal blistering eruption were reported6.